921 results match your criteria: "Fundacion Jimenez Diaz University Hospital[Affiliation]"

Puzzles, challenges, and information reservoir of SARS-CoV-2 quasispecies.

J Virol

December 2023

Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, Madrid, Spain.

Upon the emergence of SARS-CoV-2 in the human population, it was conjectured that for this coronavirus the dynamic intra-host heterogeneity typical of RNA viruses would be toned down. Nothing of this sort is observed. Here we review the main observations on the complexity and diverse composition of SARS-CoV-2 mutant spectra sampled from infected patients, within the framework of quasispecies dynamics.

View Article and Find Full Text PDF

Background: The term sepsis refers to a complex and heterogeneous syndrome. Although great progress has been made in improving the diagnosis and treatment of this condition, it continues to have a huge impact on morbidity and mortality worldwide. Mesenchymal stem cells are a population of multipotent cells that have immunomodulatory properties, anti-apoptotic effects, and antimicrobial activity.

View Article and Find Full Text PDF
Article Synopsis
  • Biliary tract tumours, such as those affecting the bile duct and gallbladder, are rare and typically diagnosed at advanced stages, leading to poor treatment options and a five-year survival rate below 20%.
  • First-line chemotherapy using gemcitabine-cisplatin shows only modest effectiveness, prompting the need for better therapeutic strategies, with the ABC-06 trial presenting FOLFOX as the standard second-line therapy.
  • While nal-IRI plus 5-FU/LV from the NIFTY trial shows promise, conflicting results from the NALIRICC trial and challenges in patient care highlight the need for more effective first-line treatments and ongoing research into tailored therapies.
View Article and Find Full Text PDF

Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases. Dealing with CV disease in patients with cancer requires special knowledge beyond that included in the general core curriculum for cardiology. Therefore, the European Society of Cardiology (ESC) has developed a special core curriculum for cardio-oncology, a consensus document that defines the level of experience and knowledge required for cardiologists in this particular field.

View Article and Find Full Text PDF

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with chronic lymphocytic leukemia (CLL) have a significantly heightened risk of developing other malignancies (OMs), with a study tracking nearly 20,000 CLL patients revealing 3,513 OMs diagnosed over 129,254 years of follow-up.
  • The study found that treatment with fludarabine and cyclophosphamide increased the likelihood of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), while non-melanoma skin cancer (NMSC) and prostate cancer were common solid tumors in treated patients.
  • Importantly, patients with CLL who developed OMs had lower overall survival rates, especially those diagnosed with AML and MDS, highlighting that C
View Article and Find Full Text PDF

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

ESMO Open

December 2023

Medical Oncology Department, Fundacion Jimenez Diaz University Hospital and Hospital General de Villalba, Madrid; Instituto de Investigación Sanitaria-Fundación Jimenez Díaz-UAM (IIS-FJD-UAM), Madrid, Spain.

Background: Conventional cytotoxic drugs are not effective in alveolar soft-part sarcoma (ASPS). Immune checkpoint (programmed cell death protein 1/programmed death-ligand 1) inhibitors (ICIs) are promising drugs in ASPS. A worldwide registry explored the efficacy of ICI in ASPS.

View Article and Find Full Text PDF

Obstructive sleep apnea and periodic limb movement in children: is there really an association?

Sleep Med

January 2024

Pediatrics Department, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain; Sleep Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain; Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040, Madrid, Spain. Electronic address:

Purpose: Periodic limb movements (PLMs) can be found isolated or related to other sleep disorders, as Obstructive Sleep Apnea (OSA). Nevertheless, this association was described before the proposal for modification of the World Association of Sleep Medicine (WASM), which incorporated major changes modifying the definition of respiratory-related leg movements (RRLM) so that the relationship between OSA and PLM could be affected.

Methods: A total of 131 PSG were studied (children with ages from 5 to 12 years old), all referred because of a suspicion of sleep-disordered breathing (65 children were diagnosed of OSA, and 66 presented snoring but no sleep apnea).

View Article and Find Full Text PDF

Objective: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping conditions. We studied whether 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is useful in identifying PMR in the setting of large vessel (LV) GCA.

Methods: LV-GCA patients diagnosed by PET-CT at a tertiary care center for a population of 450,000 people over a two-year period were reviewed.

View Article and Find Full Text PDF

: patient-derived xenografts (PDXs) have defined the field of translational cancer research in recent years, becoming one of the most-used tools in early drug development. The process of establishing cancer models in mice has turned out to be challenging, since little research focuses on evaluating which factors impact engraftment success. We sought to determine the clinical, pathological, or molecular factors which may predict better engraftment rates in PDXs.

View Article and Find Full Text PDF

Background Aims: Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is a highly challenging disease to treat. Systemic chimeric antigen receptor (CAR) T cells have shown impressive efficacy in hematologic malignancies but have been less effective in solid tumors. We explored whether intraperitoneal (i.

View Article and Find Full Text PDF

Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week.

J Am Coll Cardiol

November 2023

Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. Electronic address:

Article Synopsis
  • Atherosclerosis, the process leading to cardiovascular disease (CVD), can begin early in life, with factors like low-density lipoprotein-cholesterol contributing even at normal levels.
  • The PRECAD trial aims to determine if aggressively controlling cardiovascular risk factors in healthy young adults (ages 20-39) can help prevent or slow down atherosclerosis.
  • The study will measure changes in total atherosclerosis burden as a primary endpoint to assess its potential impact on preventing cardiovascular events later in life.
View Article and Find Full Text PDF

Introduction: This study provides an overview of the development of the first drug authorized for use in cell therapy.

Areas Covered: We analyze the case of darvadstrocel, an example of a successful cell-therapy drug used worldwide to treat Crohn's perianal fistula. A bibliographic-historical analysis of the first cellular treatment approved by the EMA, including relevant aspects concerning the authors, who were involved in the whole process.

View Article and Find Full Text PDF

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing.

Cancer Treat Rev

January 2024

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italy. Electronic address:

Cholangiocarcinomas (CCA) are a heterogeneous group of tumors that are classified as intrahepatic, perihilar, or distal according to the anatomic location within the biliary tract. Each CCA subtype is associated with distinct genomic alterations, including single nucleotide variants, copy number variants, and chromosomal rearrangements or gene fusions, each of which can influence disease prognosis and/or treatment outcomes. Molecular profiling using next-generation sequencing (NGS) is a powerful technique for identifying unique gene variants carried by an individual tumor, which can facilitate their accurate diagnosis as well as promote the optimal selection of gene variant-matched targeted treatments.

View Article and Find Full Text PDF

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis.

View Article and Find Full Text PDF

Novel mediator in anaphylaxis: decreased levels of miR-375-3p in serum and within extracellular vesicles of patients.

Front Immunol

November 2023

Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Introduction: Anaphylaxis is among the most severe manifestations of allergic disorders, but its molecular basis remains largely unknown and reliable diagnostic markers are not currently available. MicroRNAs (miRNAs) regulate several pathophysiological processes and have been proposed as non-invasive biomarkers. Therefore, this study aims to evaluate their involvement in anaphylactic reaction and their value as biomarkers.

View Article and Find Full Text PDF

Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature.

Cancers (Basel)

October 2023

Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD), 28015 Madrid, Spain.

Article Synopsis
  • * Pazopanib is the most commonly used systemic therapy for GCTs, showing disease control in 80% of patients and an objective response in 40% during a median treatment time of seven months.
  • * Molecular studies indicate that the effectiveness of pazopanib may be linked to genetic factors that enhance certain signaling pathways, and while there are other targeted therapies, pazopanib remains a promising treatment option for advanced GCTs.
View Article and Find Full Text PDF

Unlabelled: Chemsex is understood as "the intentional use of stimulant drugs to have sex for an extended time among gay, bisexual, and other men who have sex with men". It is a public health problem because of the increased incidence of cases and because of the consequences on the physical and mental health of those who practice it.

Aim: This study aimed to analyze, with the help of the Delphi method, the content validity of a new instrument to assess the risk of behaviors associated with the chemsex phenomenon.

View Article and Find Full Text PDF

Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.

Cancer Treat Rev

December 2023

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.

Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations, such as fibroblast growth factor receptor-2 (FGFR-2) fusions, and has thus led to the development of a wide spectrum of compounds. Despite favourable response rates, especially with the latest generation FGFRi, there are still a proportion of patients who will not achieve a radiological response to treatment, or who will have disease progression as the best response.

View Article and Find Full Text PDF

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.

ESMO Open

December 2023

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada; Medical Oncology, Margaret Cancer Centre, Toronto, Canada.

View Article and Find Full Text PDF
Article Synopsis
  • Epithelioid sarcoma (EpS) is a rare and aggressive soft-tissue cancer mostly seen in adolescents and young adults, with a high mortality rate of about 50% despite aggressive treatment approaches.
  • EpS has two main subtypes: a less aggressive distal (classic) type and a more dangerous proximal type, both characterized by a typical loss of the INI1 protein due to genetic changes.
  • Recent advancements, like the approval of the EZH2 inhibitor tazemetostat and efforts in developing immunotherapy, have shown limited success, highlighting the urgent need for new targeted therapies and the establishment of a collaborative research community to drive progress.
View Article and Find Full Text PDF